Efficacy and safety of canagliflozin as add‐on therapy to a glucagon‐like peptide‐1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52‐week, open‐label, phase IV study

Sodium‐glucose co‐transporter‐2 (SGLT2) inhibitors and glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) are antihyperglycaemic agents with weight‐lowering effects. The efficacy and safety of the SGLT2 inhibitor canagliflozin as add‐on therapy in Japanese patients with type 2 diabetes mellitus (T...

Descripción completa

Detalles Bibliográficos
Autores principales: Harashima, Shin‐ichi, Inagaki, Nobuya, Kondo, Kazuoki, Maruyama, Nobuko, Otsuka, Makiko, Kawaguchi, Yutaka, Watanabe, Yumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2018
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6033027/
https://www.ncbi.nlm.nih.gov/pubmed/29473709
http://dx.doi.org/10.1111/dom.13267

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6033027/
https://www.ncbi.nlm.nih.gov/pubmed/29473709
http://dx.doi.org/10.1111/dom.13267

Ejemplares similares